A study led by researchers at the University of Arizona Comprehensive Cancer Center reveals that the loss of the Y chromosome in male immune cells impairs immune function and may explain lower cancer survival rates in men.
The research, published in Nature, delves into the phenomenon of 'loss of Y' (LOY) in immune cells, particularly T lymphocytes, and its impact on cancer immunosurveillance.
LOY in white blood cells weakens the cytotoxic response of T cells, hindering their ability to identify and destroy cancer cells effectively.
The study found that LOY is not limited to malignant epithelial cells but also affects surrounding noncancerous components, suggesting a systemic influence on cancer pathogenesis.
T cells lacking the Y chromosome exhibit compromised functional capacities, enabling tumors to evade immune detection and facilitate disease progression.
Men with LOY in both cancerous cells and T cells tend to have more aggressive cancers and lower survival rates, emphasizing the synergistic impact of chromosomal aberrations.
The findings urge pre-treatment screening of patient-derived immune cells for LOY to optimize therapeutic outcomes, especially in immunotherapies like CAR T cell therapy.
Dr. Dan Theodorescu and Dr. Simon Knott spearheaded the study, shedding light on the intersection of chromosomal loss, immune function, and cancer prognosis.
The research not only advances cancer biology but also paves the way for personalized medicine strategies targeting male-specific vulnerabilities in cancer biology.
Genomic sequencing techniques were used to identify LOY-related changes in immune cells, providing insights into the molecular basis of immune dysfunction associated with LOY.
The study's implications extend beyond oncology, offering promise for understanding immune dysfunction in other age-related diseases, with potential for broader biomedical applications.